| Literature DB >> 20962323 |
Hervé Avet-Loiseau1, Florent Malard, Loic Campion, Florence Magrangeas, Catherine Sebban, Bruno Lioure, Olivier Decaux, Thierry Lamy, Laurence Legros, Jean-Gabriel Fuzibet, Mauricette Michallet, Bernadette Corront, Pascal Lenain, Cyrille Hulin, Claire Mathiot, Michel Attal, Thierry Facon, Jean-Luc Harousseau, Stephane Minvielle, Philippe Moreau.
Abstract
Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma.Entities:
Mesh：
Year: 2010 PMID： 20962323 DOI： 10.1182/blood-2010-07-295105
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113